J&J Reorganizes DePuy Synthes, Eliminates Jobs
This article was originally published in The Gray Sheet
The move, which includes about 400 job cuts and 80 new positions, is a response to “seismic shifts” in the health care market, the company said.
You may also be interested in...
Medtronic’s massive acquisition of Covidien could accelerate the trend of industry consolidation further, some say. But executives from several big device firms insist nothing fundamental has changed.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.